Does denosumab increase the risk of kidney stones in patients, especially those with a prior history of nephrolithiasis or who are receiving calcium or vitamin D supplementation?

Denosumab Does Not Increase Kidney Stone Risk

Denosumab itself does not increase the risk of kidney stones; however, the calcium supplementation required with denosumab therapy—particularly in patients with chronic kidney disease—may theoretically increase nephrolithiasis risk, though this is distinct from the drug's direct effects.

Understanding the Evidence

The comprehensive Endocrine Society guidelines 1 and FDA labeling 2 for denosumab extensively detail adverse events including hypocalcemia, infections, osteonecrosis of the jaw, and atypical femoral fractures. Notably absent from these detailed safety profiles is any mention of kidney stones or nephrolithiasis as a complication of denosumab therapy.

The Calcium Supplementation Caveat

The distinction here is critical: while denosumab itself doesn't cause kidney stones, the mandatory calcium and vitamin D supplementation required with denosumab therapy introduces a separate consideration. The guidelines emphasize that calcium supplementation (not denosumab) carries a modest increased risk of nephrolithiasis 3. Specifically:

• Calcium supplements showed a relative risk of 1.17 for nephrolithiasis in the WHI trial 3
• This risk appears dose-dependent with supplemental calcium 3
• Conversely, dietary calcium intake is associated with lower kidney stone risk, likely due to reduced intestinal oxalate absorption 3

Clinical Algorithm for Denosumab Use

Pre-Treatment Assessment

• Correct pre-existing hypocalcemia before initiating therapy 1, 2
• Assess renal function (eGFR) and evaluate for CKD-MBD 1
• Check baseline serum calcium, phosphorus, magnesium, vitamin D, and PTH 1
• In patients with prior nephrolithiasis: consider dietary calcium sources over supplements when possible

Supplementation Strategy

All patients require calcium and vitamin D supplementation 1, 2, 4:

• This is non-negotiable—no patient should receive denosumab without adequate supplementation 4
• In the pivotal study, no adequately supplemented patient developed hypocalcemia 4
• For patients with kidney stone history: emphasize dietary calcium intake and maintain adequate hydration

Monitoring Protocol

Standard monitoring (normal renal function):

• Check serum calcium before each 6-month dose 1
• Educate patients on hypocalcemia symptoms 1

Intensive monitoring (CKD stages 3b-5 or dialysis):

• Check calcium, phosphorus, magnesium within 14 days post-injection 1, 2
• Monitor at 1-3 months when calcium nadirs and PTH peaks occur 5, 6
• Expect PTH elevation of 125-200% in first 1-3 months, normalizing by 6 months 5
• Risk of hypocalcemia ranges from 14-25% in CKD patients without adequate supplementation 1

Special Populations

Chronic Kidney Disease Patients

Denosumab can be safely used in CKD stages 1-4 with appropriate precautions 1, 7, 8:

• No dose adjustment needed based on renal function 2, 4
• Fracture reduction efficacy maintained in CKD stages 1-3 1
• Stage 4 CKD: BMD improvement demonstrated but fracture efficacy uncertain 1
• Dialysis patients: require aggressive calcium/vitamin D supplementation and close monitoring 7, 8, 9, 6

Critical Pitfalls to Avoid

1. Never delay or skip doses: Rebound vertebral fractures occur with treatment interruption 1—administer every 6 months precisely 1

2. Never discontinue without transition therapy: Bone turnover rebounds within 3-6 months, BMD returns to baseline by 18-24 months 1—transition to bisphosphonate if stopping 1

3. Never initiate without supplementation: The risk of severe hypocalcemia is unacceptable without calcium and vitamin D 4—two patients required hospitalization for IV calcium in the renal impairment study when supplementation was initially not mandated 4

4. Never assume kidney stones are from denosumab: If nephrolithiasis develops, evaluate calcium supplementation regimen and hydration status, not the denosumab itself

Bottom Line for Kidney Stone Concerns

Denosumab does not cause kidney stones. If you have a patient with prior nephrolithiasis requiring denosumab:

• Proceed with denosumab therapy
• Optimize calcium intake through diet rather than high-dose supplements when feasible
• Ensure adequate hydration
• Monitor appropriately based on renal function
• The fracture reduction benefits (68% vertebral, 39% hip, 19% nonvertebral fractures) 1 far outweigh theoretical concerns about calcium supplementation and stones in most patients